TBRG vs. CLRB, IMUX, RLMD, ASRT, COYA, FGEN, NOTV, LIFE, LIFW, and TELA
Should you be buying TruBridge stock or one of its competitors? The main competitors of TruBridge include Cellectar Biosciences (CLRB), Immunic (IMUX), Relmada Therapeutics (RLMD), Assertio (ASRT), Coya Therapeutics (COYA), FibroGen (FGEN), Inotiv (NOTV), aTyr Pharma (LIFE), MSP Recovery (LIFW), and TELA Bio (TELA). These companies are all part of the "medical" sector.
Cellectar Biosciences (NASDAQ:CLRB) and TruBridge (NASDAQ:TBRG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking.
Cellectar Biosciences presently has a consensus target price of $20.00, suggesting a potential upside of 528.93%. TruBridge has a consensus target price of $18.50, suggesting a potential upside of 110.23%. Given TruBridge's higher probable upside, research analysts plainly believe Cellectar Biosciences is more favorable than TruBridge.
Cellectar Biosciences received 237 more outperform votes than TruBridge when rated by MarketBeat users. However, 100.00% of users gave TruBridge an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 88.6% of TruBridge shares are owned by institutional investors. 4.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 3.6% of TruBridge shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cellectar Biosciences has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, TruBridge has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.
In the previous week, TruBridge had 11 more articles in the media than Cellectar Biosciences. MarketBeat recorded 20 mentions for TruBridge and 9 mentions for Cellectar Biosciences. TruBridge's average media sentiment score of 0.11 beat Cellectar Biosciences' score of -0.05 indicating that Cellectar Biosciences is being referred to more favorably in the media.
Cellectar Biosciences has a net margin of 0.00% compared to Cellectar Biosciences' net margin of -15.27%. Cellectar Biosciences' return on equity of 8.44% beat TruBridge's return on equity.
Cellectar Biosciences has higher earnings, but lower revenue than TruBridge. TruBridge is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Cellectar Biosciences beats TruBridge on 9 of the 15 factors compared between the two stocks.
Get TruBridge News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBRG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBRG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TruBridge Competitors List
Related Companies and Tools
